FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
PureTech Health plc Stock AnalysisComprehensive stock analysis for PureTech Health plc (PTCHF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPTCHF
PTCHF
PureTech Health plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PTCHF
Home🔹Stocks🔹PureTech Health plc

PureTech Health plc

🇺🇸PTCHF•OTC

PureTech Health plc

🇺🇸PTCHF•OTC
Market cap
$410.38M
Sentiment

Your view on PTCHF

Mkt Cap
$410.38M
Sentiment
Your view
PTCHF
PureTech Health plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PTCHF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About PureTech Health plc

Industry
Biotechnology
Sector
Healthcare
CEO
Robert Lyne
Headquarters
6 Tide Street, Boston, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Robert Lyne
Headquarters
6 Tide Street, Boston, MA, US
Description

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States.

The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.

It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs.

In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation.

PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for PureTech Health plc, and the rating behind it. PTCHF last traded at $1.70; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for PureTech Health plc. Starting points for PureTech Health plc: EPS -$0.47, beta 0.72 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for PureTech Health plc. PureTech Health plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for PureTech Health plc. Trailing twelve-month EPS for PureTech Health plc stands at -$0.47. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for PureTech Health plc. PureTech Health plc has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

PureTech Health plc valued side by side against its closest peers. PureTech Health plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold PureTech Health plc, and how their positions are changing. At a $410.4M market value, institutional positions materially move PureTech Health plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by PureTech Health plc executives and directors. Shares of PureTech Health plc have traded between $1.27 and $1.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming PureTech Health plc. PureTech Health plc is a $410.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming PureTech Health plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for PureTech Health plc. Coverage tracks PureTech Health plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • AVCTF — Avacta Group Plc
  • BOVNF — BioInvent International AB (publ)
  • CLVLF — Clinuvel Pharmaceuticals Limited
  • FGHQF — Frontage Holdings Corporation
  • HLOSF — Healios K.K.
  • HUMDF — Hua Medicine (Shanghai) Ltd.
  • MDCLF — MedinCell S.A.

More Biotechnology companies

  • OCEA — Ocean Biomedical, Inc.
  • OCGN — Ocugen, Inc.
  • OCS — Oculis Holding AG
  • MGNX — MacroGenics, Inc.
  • MGTX — MeiraGTx Holdings plc
  • MGX — Metagenomi, Inc. Common Stock
  • MIR.V — MedMira Inc.
  • MIRM — Mirum Pharmaceuticals, Inc.
  • MIST — Milestone Pharmaceuticals Inc.
  • MLEC — Moolec Science S.A.
  • MLECW — Moolec Science S.A.
  • MLLCF — Molecular Partners AG

News

Latest Market News